0001209191-13-007127.txt : 20130207 0001209191-13-007127.hdr.sgml : 20130207 20130207173201 ACCESSION NUMBER: 0001209191-13-007127 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130205 FILED AS OF DATE: 20130207 DATE AS OF CHANGE: 20130207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kelly Lisa CENTRAL INDEX KEY: 0001349077 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 13583547 MAIL ADDRESS: STREET 1: 125 SPRING STREET CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6173416100 MAIL ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-02-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001349077 Kelly Lisa C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE MA 02139 0 1 0 0 SVP, Human Resources Common Stock 2013-02-05 4 A 0 10166 0.01 A 25382 D Common Stock 1965 I 401(k) Employee Stock Option (right to buy) 45.11 2013-02-05 4 A 0 45750 0.00 A 2023-02-04 Common Stock 45750 45750 D Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Omar White, Attorney-In-Fact 2013-02-07